Edition:
United Kingdom

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

3.71USD
18 Jan 2019
Change (% chg)

-- (--)
Prev Close
$3.71
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
36,954
52-wk High
$23.67
52-wk Low
$3.39

Latest Key Developments (Source: Significant Developments)

Mersana Therapeutics reports third quarter results
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q3 LOSS PER SHARE $0.75.Q3 EARNINGS PER SHARE VIEW $-0.59 -- THOMSON REUTERS I/B/E/S.XMT-1536 PHASE 1 DOSE ESCALATION ONGOING WITH DATA EXPECTED IN FIRST HALF OF 2019.XMT-1522 PHASE 1 DOSE ESCALATION ENROLLMENT RESUMED.MERSANA THERAPEUTICS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF SEPT 30, 2018, WERE $86.1 MILLION, COMPARED TO $125.2 MILLION AS OF DEC 31, 2017.MERSANA THERAPEUTICS - CO EXPECTS THAT CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL ENABLE IT TO FUND ITS OPERATING PLAN INTO 2020.  Full Article

Mersana Therapeutics Trial Placed On Hold By FDA After Patient Death
Thursday, 19 Jul 2018 

July 19 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES PARTIAL CLINICAL HOLD FOR XMT-1522 CLINICAL TRIAL.MERSANA THERAPEUTICS INC - FDA PLACED PHASE 1 STUDY OF XMT-1522 ON PARTIAL CLINICAL HOLD.MERSANA THERAPEUTICS - PARTIAL CLINICAL HOLD INITIATED FOLLOWING MERSANA'S REPORT TO FDA OF GRADE 5 SERIOUS ADVERSE EVENT (PATIENT DEATH).MERSANA THERAPEUTICS - PARTIAL CLINICAL HOLD DOES NOT AFFECT ONGOING CLINICAL DEVELOPMENT OF MERSANA'S PRODUCT CANDIDATE XMT-1536.MERSANA THERAPEUTICS - PARTIAL CLINICAL HOLD INITIATED ON STUDY AFTER A PATIENT DEATH.  Full Article

Mersana Therapeutics Files For Mixed Shelf Of Up To $250 Mln - SEC Filing
Monday, 2 Jul 2018 

July 2 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING.  Full Article

Mersana Presents Interim Dose-Escalation Data On XMT-1522 In Select Cancers At Asco 2018
Monday, 4 Jun 2018 

June 4 (Reuters) - Mersana Therapeutics Inc ::MERSANA PRESENTS INTERIM DOSE-ESCALATION DATA ON XMT-1522 IN SELECT CANCERS AT ASCO 2018.MERSANA THERAPEUTICS-NEW EFFICACY,SAFETY DATA FROM ONGOING PHASE 1 DOSE-ESCALATION&EXPANSION STUDY EVALUATING CO'S INVESTIGATIONAL COMPOUND, XMT-1522.  Full Article

Mersana Therapeutics Reports Q1 Loss Per Share $0.54
Monday, 14 May 2018 

May 14 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q1 LOSS PER SHARE $0.54.Q1 EARNINGS PER SHARE VIEW $-0.61 -- THOMSON REUTERS I/B/E/S.COLLABORATION REVENUE FOR Q1 2018 WAS APPROXIMATELY $3.1 MILLION, COMPARED TO $4.3 MILLION.Q1 REVENUE VIEW $3.7 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Mersana Therapeutics Q4 Loss Per Share $0.61
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Mersana Therapeutics Inc ::MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES.Q4 LOSS PER SHARE $0.61.Q4 EARNINGS PER SHARE VIEW $-0.50 -- THOMSON REUTERS I/B/E/S.ENROLLMENT ON TRACK FOR PHASE 1 TRIAL OF XMT-1522 PATIENTS WITH ADVANCED TUMORS EXPRESSING HER2.COLLABORATION REVENUE FOR Q4 2017 WAS ABOUT $3.3 MILLION VERSUS $12.0 MILLION FOR SAME PERIOD IN 2016.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF DECEMBER 31, 2017 WERE $125.2 MILLION.MERSANA THERAPEUTICS - EXPECTS CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES WILL ENABLE CO TO FUND OPERATING PLAN THROUGH AT LEAST MID-2019.  Full Article

Mersana announces third quarter loss of $0.35 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Mersana Therapeutics Inc :Mersana announces third quarter 2017 financial results and provides business updates.Qtrly ‍loss per share $0.35​.Cash, cash equivalents and marketable securities as of Sept 30, 2017 were $133.4 million, compared with $100.3 million as of Dec 31, 2016​.Expects that cash, cash equivalents and marketable securities will enable it to fund operating plan through at least mid-2019​.  Full Article

Mersana announces FDA clearance of IND application for XMT-1536
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Mersana Therapeutics Inc :Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b.‍U.S. FDA cleared company's investigational new drug application to begin phase 1 clinical trials for XMT-1536​.  Full Article

Mersana Therapeutics says Pfizer reports 9.8 percent passive stake in Mersana as of July 3 - SEC Filing
Thursday, 13 Jul 2017 

July 13 (Reuters) - Mersana Therapeutics Inc :Pfizer Inc. reports 9.8 percent passive stake in Mersana Therapeutics Inc as of July 3 - sec filing.  Full Article

Rock Springs Capital Management reports 6.8 pct passive stake in Mersana Therapeutics as of June 28, 2017
Friday, 7 Jul 2017 

July 7 (Reuters) - Rock Springs Capital Management LP: :Rock Springs Capital Management LP reports a 6.8 percent passive stake in Mersana Therapeutics Inc as of June 28, 2017 - sec filing.  Full Article